000167921 001__ 167921
000167921 005__ 20240229133554.0
000167921 0247_ $$2pmid$$apmid:33722709
000167921 0247_ $$2ISSN$$a1556-0864
000167921 0247_ $$2ISSN$$a1556-1380
000167921 0247_ $$2doi$$adoi:10.1016/j.jtho.2021.02.024. 
000167921 0247_ $$2doi$$adoi:10.1016/j.jtho.2021.02.024.
000167921 037__ $$aDKFZ-2021-00640
000167921 041__ $$aEnglish
000167921 082__ $$a610
000167921 1001_ $$aAredo, Jacqueline V$$b0
000167921 245__ $$aTobacco Smoking and Risk of Second Primary Lung Cancer.
000167921 260__ $$aAmsterdam$$bElsevier$$c2021
000167921 3367_ $$2DRIVER$$aarticle
000167921 3367_ $$2DataCite$$aOutput Types/Journal article
000167921 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1625051745_24032
000167921 3367_ $$2BibTeX$$aARTICLE
000167921 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000167921 3367_ $$00$$2EndNote$$aJournal Article
000167921 500__ $$a16(6):968-979
000167921 520__ $$aLung cancer survivors are at high risk of a second primary lung cancer (SPLC). However, SPLC risk factors have not been established and the impact of tobacco smoking remains controversial. We examined risk factors for SPLC across multiple epidemiologic cohorts and assessed the impact of smoking cessation on reducing SPLC risk.We analyzed data from 7,059 participants in the Multiethnic Cohort (MEC) diagnosed with an initial primary lung cancer (IPLC) between 1993 and 2017. Cause-specific proportional hazards models estimated SPLC risk. We conducted validation studies using the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO, N=3,423 IPLC cases) and European Prospective Investigation into Cancer and Nutrition (EPIC, N=4,731 IPLC cases) cohorts and pooled the SPLC risk estimates using random effects meta-analysis.Overall, 163 (2.3%) MEC cases developed a SPLC. Smoking pack-years (HR 1.18 per 10 pack-years; P<0.001) and smoking intensity (HR 1.30 per 10 cigarettes per day (CPD); P<0.001) were significantly associated with increased SPLC risk. Individuals who met the 2013 U.S. Preventive Services Task Force's (USPSTF) screening criteria at IPLC diagnosis also had an increased SPLC risk (HR 1.92; P<0.001). Validation studies with PLCO and EPIC showed consistent results. Meta-analysis yielded pooled HRs of 1.16 per 10 pack-years (Pmeta<0.001), 1.25 per 10 CPD (Pmeta<0.001), and 1.99 (Pmeta<0.001) for meeting the USPSTF criteria. In MEC, smoking cessation after IPLC diagnosis was associated with an 83% reduction in SPLC risk (HR 0.17; P<0.001).Tobacco smoking is a risk factor for SPLC. Smoking cessation after IPLC diagnosis may reduce the risk of SPLC. Additional strategies for SPLC surveillance and screening are warranted.
000167921 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000167921 588__ $$aDataset connected to DataCite, PubMed,
000167921 650_7 $$2Other$$ascreening
000167921 650_7 $$2Other$$asecond primary lung cancer
000167921 650_7 $$2Other$$asmoking cessation
000167921 650_7 $$2Other$$asurveillance
000167921 650_7 $$2Other$$atobacco smoking
000167921 7001_ $$aLuo, Sophia J$$b1
000167921 7001_ $$aGardner, Rebecca M$$b2
000167921 7001_ $$aSanyal, Nilotpal$$b3
000167921 7001_ $$aChoi, Eunji$$b4
000167921 7001_ $$aHickey, Thomas P$$b5
000167921 7001_ $$aRiley, Thomas L$$b6
000167921 7001_ $$aHuang, Wen-Yi$$b7
000167921 7001_ $$aKurian, Allison W$$b8
000167921 7001_ $$aLeung, Ann N$$b9
000167921 7001_ $$aWilkens, Lynne R$$b10
000167921 7001_ $$aRobbins, Hilary A$$b11
000167921 7001_ $$aRiboli, Elio$$b12
000167921 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b13$$udkfz
000167921 7001_ $$aTjønneland, Anne$$b14
000167921 7001_ $$aVermeulen, Roel C H$$b15
000167921 7001_ $$aPanico, Salvatore$$b16
000167921 7001_ $$aLe Marchand, Loïc$$b17
000167921 7001_ $$aAmos, Christopher I$$b18
000167921 7001_ $$aHung, Rayjean J$$b19
000167921 7001_ $$aFreedman, Neal D$$b20
000167921 7001_ $$aJohansson, Mattias$$b21
000167921 7001_ $$aCheng, Iona$$b22
000167921 7001_ $$aWakelee, Heather A$$b23
000167921 7001_ $$aHan, Summer S$$b24
000167921 773__ $$0PERI:(DE-600)2223437-8$$a10.1016/j.jtho.2021.02.024.$$n6$$p968-979$$tJournal of thoracic oncology$$v16$$x1556-0864$$y2021
000167921 909CO $$ooai:inrepo02.dkfz.de:167921$$pVDB
000167921 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000167921 9130_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000167921 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000167921 9141_ $$y2021
000167921 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz$$d2021-01-26$$wger
000167921 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ THORAC ONCOL : 2019$$d2021-01-26
000167921 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-26
000167921 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-26
000167921 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-26
000167921 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-26
000167921 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-01-26
000167921 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-26
000167921 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-26
000167921 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bJ THORAC ONCOL : 2019$$d2021-01-26
000167921 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000167921 980__ $$ajournal
000167921 980__ $$aVDB
000167921 980__ $$aI:(DE-He78)C020-20160331
000167921 980__ $$aUNRESTRICTED